Shanghai Rongheng Pharmaceutical

Shanghai Rongheng Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics. Founded in 2018, the company focuses on high-value targets in oncology and immunology, utilizing its proprietary drug discovery platform to develop "First-in-class" and "Best-in-class" medicines. Its lead candidate, RH001, is a highly selective USP1 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. The company is backed by prominent venture capital firms and aims to address significant unmet medical needs globally.